When will the FDA approve Intellia Therapeutics' lonvo-z?
As of Sat, 21 Nov 2026 13:04:17 UTC, Kalshi traders price Before October 2027 (93.0%), Before 2028 (93.0%), Before July 2027 (91.0%). The market has $7K in volume and closes on Sat, 01 Jan 2028.
Updated:
Current odds
| Outcome | Chance | Yes price | No price |
|---|---|---|---|
| Before October 2027 | 93.0% | 93.0¢ | 7.0¢ |
| Before 2028 | 93.0% | 93.0¢ | 7.0¢ |
| Before July 2027 | 91.0% | 91.0¢ | 9.0¢ |
Market details
- Venue: Kalshi
- Volume: $7K
- Liquidity: $7K
- Closes:
Resolution rules
Each outcome is a separate contract with its own rules. The rules for Before October 2027:
If the FDA approves Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema for marketing before Oct 1, 2027, then the market resolves to Yes.
Sources
Related markets
- Will the FDA approve retatrutide?
- Tesla Optimus released this year?
- How many launches will SpaceX have this year?
- When will any company achieve AGI?
- How many launches will SpaceX have in November?
- When will Apple release the iPhone 18?
More markets like this
- Will the FDA approve a cure for Type 1 diabetes before 2033?
- Will the FDA approve CagriSema?
- Will the FDA approve VERVE-102?
- FDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (this year)
- When will the first 2028 Republican primary debate be?
- When will the first listed Democrat announce a 2028 presidential run?
- When will the first listed Republican announce a 2028 presidential run?
- When will the first useful quantum computer be developed?
A price on DOXA is the market-implied probability of an outcome on the venue that lists it. It is what traders are paying, not a forecast made by DOXA, and it is not investment advice. How DOXA shows prices · Terms of Use
DOXA is a liquidity aggregator for prediction markets that compares odds and depth across Polymarket, Kalshi and others and routes each trade for best execution with an AI assistant.